Morepen Laboratories Reports Record Q2 and H1 FY27 Revenue and Earnings Growth
Morepen Laboratories reported record financial results for Q2 and H1 FY27, with sales revenue rising 81% to Rs. 755 crore in Q2 and 57% to Rs. 1,330 crore in H1. EBITDA surged 273% to Rs. 132 crore in Q2 and 243% to Rs. 220 crore in H1, while PAT increased 117% and 177% respectively. Growth was driven by expanded CDMO commercial supplies, exports doubling to Rs. 654 crore in H1, and increased medical device sales. The company also advanced its API CDMO capacity and submitted its first U.S. ANDA.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (83/100). Lens Score 35/100.
Outlets measured: businessstandard, thetribune, freepressjournal. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (78–85/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
freepressjournal broke this story on 27 Oct, 08:22 am. Other outlets followed.